PTSD

Preliminary Phase 1b data demonstrated the favorable safety and tolerability profile of VLS-01 buccal film, with psychedelic effects resolved by 120 minutes.

Cristina Pearse, an MDMA-assisted therapy trial participant, expresses disappointment in the FDA’s decision not to approve MDMA-assisted therapy.

The US FDA has issued a CRL and requested an additional phase 3 trial for MDMA-assisted therapy in the management of PTSD.

A study suggests TMR can boost PTSD treatment by enhancing memory consolidation during sleep, showing significant symptom reduction without affecting sleep quality.

PTSD experts explore unmet PTSD needs, the potential of psychedelic therapies, and key unanswered questions about MDMA-assisted therapy for PTSD.

A recent study found a high prevalence of head injuries among law enforcement officers may make them more prone to experiencing mental health issues.

In an interview with HCPLive, Angela Moreland, PhD, highlighted the largest takeaway from the study on the psychiatric impact of mass shootings on the greater community.

A new study found probable PTSD was prevalent among adults in the community after a mass shooting, with greater prevalence among those previously assaulted.

In this part of our 5-part series, Gus Alva, MD talks about MDMA's efficacy in controlled settings and addresses misconceptions.

In this part of our 5-part series, Gus Alva, MD discusses the unmet need in PTSD treatment and the potential of MDMA-assisted therapy.

Dunlop discusses what the next steps for MDMA-assisted therapy would be if approved.

Dunlop provided his opinions on the committee’s comments regarding functional unblinding and cardiovascular implicative risks when it comes to studying MDMA.

Family physician Scuderi shares how he helps patients manage PTSD symptoms ahead of Fourth of July fireworks.

FDA accepts a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, with a PDUFA date of February 8, 2025.

The study APEX-002-B01-02 will evaluate how APEX-52, a microdose psilocybin, can impact safe driving.

Follow HCPLive's coverage of the full-day FDA committee meeting regarding Lykos Therapeutics' application for MDMA-assisted therapy as a novel treatment for patients with PTSD.

Ahead of the FDA decision on MDMA-assisted therapy to treat PTSD this summer, van der Kolk shares his thoughts on the logistics of care.

Emerson previews the highly anticipated FDA advisory committee this week, and Lykos' plans for rolling out MDMA-assisted therapy in the event it is approved to treat PTSD.

New data presented at SLEEP 2024 show sleep disorders including insomnia are only linked to worse quality of life when veterans do not also have PTSD.

Van der Kolk discusses the long-term outlook of MDMA in patients with PTSD and what further outcomes he'd like to see explored in the space.

The FDA will decide on an application this summer for the treatment of PTSD with MDMA-assisted therapy. A renowned researcher explains how the treatment benefits patients with trauma.

The new psychedelic CPT codes, effective January 1, 2024, could impact MDMA if approved. The FDA's Psychopharmacologic Drugs Advisory Committee will discuss MDMA on June 4.

Compass Pathways reports positive results for psilocybin in PTSD treatment, showing safety and symptom improvement in an open-label phase 2 study.

Lykos Therapeutics' new drug application for MDMA plus psychiatric intervention for adults with PTSD will be the first reviewed by an FDA committee for such a therapy.

Marmar explains what anticipated blood and molecular profiling of PTSD may provide psychiatrists treating patients.

New literature review data suggests doxazosin is related to less incident hypotension than prazosin, while providing clinical benefit, in PTSD patients with condition-related nightmares.

A new study found individuals with PTSD face rapid transitions between neutral and negative emotional states.

Lykos Therapeutics announced the FDA accepted its NDA for MDMA-assisted therapy for individuals with PTSD on February 9, 2024, backed by phase 3 data showing the drug’s efficacy.

The study found the odds of a perinatal PTSD diagnosis were greater for people aged 15 – 26 years, more comorbidities, and a lower income of poverty.

This March 2024 psychiatry month in review highlights positive phase 2b and phase 2a data for drugs targeting treatment-resistant depression, generalized anxiety disorder, and PTSD.